OS01.7 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas

E. H. Bell; P. Zhang; K. Aldape; J. McElroy; M. Mehta; J. Fleming; Z. Liu; S. Coons; D. Johnson; A. Chakravarti

doi:10.1093/neuonc/nox036.006

OS01.7 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas

E. H. Bell
, P. Zhang
, K. Aldape
, J. McElroy
, M. Mehta
, J. Fleming
, Z. Liu
, S. Coons
, D. Johnson
, A. Chakravarti

Herbert Wertheim Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Neuro-oncology
Volume	19
DOIs	https://doi.org/10.1093/neuonc/nox036.006
State	Published - May 1 2017

Disciplines

Genetics
Pathology
Other Medical Specialties

Access to Document

10.1093/neuonc/nox036.006License: Unspecified

Cite this

Bell, E. H., Zhang, P., Aldape, K., McElroy, J., Mehta, M., Fleming, J., Liu, Z., Coons, S., Johnson, D., & Chakravarti, A. (2017). OS01.7 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas. Neuro-oncology, 19. https://doi.org/10.1093/neuonc/nox036.006

@article{b72247b6c23b405d8b3eaf57ad0e4ed8,

title = "OS01.7 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas",

author = "Bell, \{E. H.\} and P. Zhang and K. Aldape and J. McElroy and M. Mehta and J. Fleming and Z. Liu and S. Coons and D. Johnson and A. Chakravarti",

note = "Background: This study sought to determine the proportion of patients with MGMT promoter methylation within NRG Oncology/RTOG 9802 and its prognostic significance in the setting of high-risk low-grade gliomas in a prospective phase III trial. Methods: NRG Oncology/RTOG 9802 enrolled 251 eligible high-risk patients, treated with RT or RT + PCV.",

year = "2017",

month = may,

day = "1",

doi = "10.1093/neuonc/nox036.006",

language = "American English",

volume = "19",

journal = "Neuro-oncology",

}

TY - JOUR

T1 - OS01.7 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas

AU - Bell, E. H.

AU - Zhang, P.

AU - Aldape, K.

AU - McElroy, J.

AU - Mehta, M.

AU - Fleming, J.

AU - Liu, Z.

AU - Coons, S.

AU - Johnson, D.

AU - Chakravarti, A.

N1 - Background: This study sought to determine the proportion of patients with MGMT promoter methylation within NRG Oncology/RTOG 9802 and its prognostic significance in the setting of high-risk low-grade gliomas in a prospective phase III trial. Methods: NRG Oncology/RTOG 9802 enrolled 251 eligible high-risk patients, treated with RT or RT + PCV.

PY - 2017/5/1

Y1 - 2017/5/1

UR - https://academic.oup.com/neuro-oncology/article-lookup/doi/10.1093/neuonc/nox036.006

U2 - 10.1093/neuonc/nox036.006

DO - 10.1093/neuonc/nox036.006

M3 - Article

VL - 19

JO - Neuro-oncology

JF - Neuro-oncology

ER -

OS01.7 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas

Disciplines

Access to Document

Other files and links

Cite this